Demographic, laboratory, and clinical characteristics of patients at last follow-up for patients without PA or at diagnosis of PA
| Characteristic . | All patients (N) . | No PA . | New-onset PA . | P value . | ||
|---|---|---|---|---|---|---|
| n . | Median (Q1, Q3) or n (%) . | n . | Median (Q1, Q3) or n (%) . | |||
| Age (y) | 119 | 99 | 28 (24, 37.5) | 20 | 33 (27, 41) | .06 |
| Sex (female) | 119 | 56 | 56 (57) | 10 | 10 (50) | .77 |
| Weight (kg) | 112 | 92 | 67.2 (58.1, 80.725) | 20 | 68.7 (60.55, 81.05) | .69 |
| SBP (mm Hg) | 114 | 94 | 116 (107.5, 121.75) | 20 | 122.5 (114, 128.75) | .02 |
| Diastolic blood pressure (mm Hg) | 114 | 94 | 68 (61, 74.5) | 20 | 69 (61.5, 75.75) | .54 |
| WBC count (×109/L) | 111 | 92 | 8.35 (5.875, 10.8) | 19 | 10.1 (8.345, 11.56) | .02 |
| Hemoglobin (g/dL) | 111 | 92 | 9.1 (8.1, 9.825) | 19 | 8.7 (7.8, 9.8) | .42 |
| Platelet count (×109/L) | 111 | 92 | 386 (280.75, 504.5) | 19 | 347 (261, 456) | .40 |
| Absolute reticulocyte count (×109/L) | 108 | 91 | 181.2 (107.4, 248.5) | 17 | 128.2 (44.64, 241.7) | 21 |
| Hemoglobin F (%) | 97 | 83 | 11.5 (5.75, 17.75) | 14 | 8.35 (2.9, 13.45) | .26 |
| Hemoglobin S (%) | 97 | 83 | 79.5 (71.05, 84.8) | 14 | 76.05 (49.875, 84.875) | .43 |
| eGFR (creatinine-based equation [mL/min per 1.73 m2]) | 112 | 92 | 122.294 (111.067, 129.589) | 20 | 118.694 (98.38, 126.609) | .34 |
| eGFR (cystatin C–based equation [mL/min per 1.73 m2]) | 90 | 78 | 107.172 (81.271, 121.898) | 12 | 81.06 (67.645, 103.552) | .19 |
| Total bilirubin (mg/dL) | 112 | 92 | 2.2 (1.4, 3.25) | 20 | 2.6 (2.075, 4.025) | .25 |
| Direct bilirubin (mg/dL) | 95 | 80 | 0.4 (0.3, 0.5) | 15 | 0.4 (0.35, 0.85) | .13 |
| Indirect bilirubin (mg/dL) | 95 | 80 | 1.8 (1.1, 2.875) | 15 | 2.2 (1.8, 3.1) | .2791 |
| Urine micro ACR (mg/g) | 109 | 89 | 11.4 (6.6, 20.1) | 20 | 174.4 (65.4, 231.0) | <.0001 |
| Use of NSAIDs (yes) | 119 | 48 | 48 (48) | 3 | 3 (15) | .01 |
| Use of hydroxyurea (yes) | 114 | 70 | 70 (74) | 10 | 10 (50) | .06 |
| Use of ACE inhibitors/ARBs (yes) | 114 | 13 | 13 (14) | 4 | 4 (20) | .72 |
| H/O acute chest syndrome (yes) | 114 | 62 | 62 (65) | 13 | 13 (68) | 1 |
| H/O stroke (yes) | 113 | 15 | 15 (16) | 3 | 3 (15) | 1 |
| H/O leg ulcers (yes) | 115 | 5 | 5 (5) | 3 | 3 (15) | .28 |
| H/O avascular necrosis (yes) | 115 | 32 | 32 (34) | 5 | 5 (25) | .62 |
| H/O priapism∗ (yes) | 46 | 14 | 14 (33) | 5 | 5 (50) | .82 |
| H/O diabetes mellitus (yes) | 113 | 3 | 3 (3) | 2 | 2 (10) | .46 |
| Characteristic . | All patients (N) . | No PA . | New-onset PA . | P value . | ||
|---|---|---|---|---|---|---|
| n . | Median (Q1, Q3) or n (%) . | n . | Median (Q1, Q3) or n (%) . | |||
| Age (y) | 119 | 99 | 28 (24, 37.5) | 20 | 33 (27, 41) | .06 |
| Sex (female) | 119 | 56 | 56 (57) | 10 | 10 (50) | .77 |
| Weight (kg) | 112 | 92 | 67.2 (58.1, 80.725) | 20 | 68.7 (60.55, 81.05) | .69 |
| SBP (mm Hg) | 114 | 94 | 116 (107.5, 121.75) | 20 | 122.5 (114, 128.75) | .02 |
| Diastolic blood pressure (mm Hg) | 114 | 94 | 68 (61, 74.5) | 20 | 69 (61.5, 75.75) | .54 |
| WBC count (×109/L) | 111 | 92 | 8.35 (5.875, 10.8) | 19 | 10.1 (8.345, 11.56) | .02 |
| Hemoglobin (g/dL) | 111 | 92 | 9.1 (8.1, 9.825) | 19 | 8.7 (7.8, 9.8) | .42 |
| Platelet count (×109/L) | 111 | 92 | 386 (280.75, 504.5) | 19 | 347 (261, 456) | .40 |
| Absolute reticulocyte count (×109/L) | 108 | 91 | 181.2 (107.4, 248.5) | 17 | 128.2 (44.64, 241.7) | 21 |
| Hemoglobin F (%) | 97 | 83 | 11.5 (5.75, 17.75) | 14 | 8.35 (2.9, 13.45) | .26 |
| Hemoglobin S (%) | 97 | 83 | 79.5 (71.05, 84.8) | 14 | 76.05 (49.875, 84.875) | .43 |
| eGFR (creatinine-based equation [mL/min per 1.73 m2]) | 112 | 92 | 122.294 (111.067, 129.589) | 20 | 118.694 (98.38, 126.609) | .34 |
| eGFR (cystatin C–based equation [mL/min per 1.73 m2]) | 90 | 78 | 107.172 (81.271, 121.898) | 12 | 81.06 (67.645, 103.552) | .19 |
| Total bilirubin (mg/dL) | 112 | 92 | 2.2 (1.4, 3.25) | 20 | 2.6 (2.075, 4.025) | .25 |
| Direct bilirubin (mg/dL) | 95 | 80 | 0.4 (0.3, 0.5) | 15 | 0.4 (0.35, 0.85) | .13 |
| Indirect bilirubin (mg/dL) | 95 | 80 | 1.8 (1.1, 2.875) | 15 | 2.2 (1.8, 3.1) | .2791 |
| Urine micro ACR (mg/g) | 109 | 89 | 11.4 (6.6, 20.1) | 20 | 174.4 (65.4, 231.0) | <.0001 |
| Use of NSAIDs (yes) | 119 | 48 | 48 (48) | 3 | 3 (15) | .01 |
| Use of hydroxyurea (yes) | 114 | 70 | 70 (74) | 10 | 10 (50) | .06 |
| Use of ACE inhibitors/ARBs (yes) | 114 | 13 | 13 (14) | 4 | 4 (20) | .72 |
| H/O acute chest syndrome (yes) | 114 | 62 | 62 (65) | 13 | 13 (68) | 1 |
| H/O stroke (yes) | 113 | 15 | 15 (16) | 3 | 3 (15) | 1 |
| H/O leg ulcers (yes) | 115 | 5 | 5 (5) | 3 | 3 (15) | .28 |
| H/O avascular necrosis (yes) | 115 | 32 | 32 (34) | 5 | 5 (25) | .62 |
| H/O priapism∗ (yes) | 46 | 14 | 14 (33) | 5 | 5 (50) | .82 |
| H/O diabetes mellitus (yes) | 113 | 3 | 3 (3) | 2 | 2 (10) | .46 |
P values are calculated from χ2 tests or Fisher exact tests if expected cell counts were small for comparing categorical characteristics and Wilcoxon-Mann-Whitney tests for comparing continuous characteristics across strata.
This complication occurs only in male patients.